Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Gastric Cancer

Presenters

Yu-ting Lee

Citation

Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422

Authors

Y. Lee1, P. Hsu2, Y. Chuang2, H. Jin3, A.S..L. Cheng4, E.K..W. Ng5, C. Liu6, Y. Chen2, F. Cheng2, M.W..Y. Chan2

Author affiliations

  • 1 Internal Medicine, Chia Yi Christian Hospital, 60002 - Chiayi City/TW
  • 2 Department Of Biomedical Sciences, National Chung Cheng University, 621 - Min Hsiung, Chiayi/TW
  • 3 Laboratory Of Cancer Biology,key Lab Of Biotherapy In Zhejiang,, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou/CN
  • 4 School Of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong/HK
  • 5 Department Of Surgery, Chinese University of Hong Kong, Hong Kong/HK
  • 6 Division Of Hematology And Oncology, Department Of Medicine, Taipei Veterans General Hospital, Taipei/TW

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 175P

Background

Helicobacter pylori-induced aberrant JAK/STAT3 signaling contributed to the development of gastric cancer. We hypothesize that activated STAT3 may epigenetically repress it’s targets by DNA methylation. The object of this study is to identified the diagnostic and prognostic value of novel STAT3 targets that are hypermethylated in gastric cancer.

Methods

Fifty patients’ clinical data and genomic DNA were collected from the Changhua Christian Hospital, Taiwan. DNA methylation microarray was used to analyze the methylation status in AGS gastric cancer cells and patient samples with different STAT3 status. Bioinformatic analyses was carried out to identify STAT3 targets with differential methylation status. Bisulphite pyrosequencing was designed and performed in cancer and normal tissue to examine the methylation level of the target genes. Receiver operating character (ROC) curve and the survival analysis were examined.

Results

We found that promoter hypomethylation of PCDHB15, a potential STAT3 target, was observed in AGS cells depleted with STAT3, while promoter hypermethylation was observed in patient samples with activated STAT3. Cell line studies found that treatment with the DNMT inhibitor, 5azaDC, restored PCDHB15 expression in AGS. Pyrosequencing in various cell lines, including AGS, MKN28, MKN45, SNU1 and SNU16, demonstrated hypermethylation of the PCDHB15 promoter. Compared to the cancer tissue, a lower PCDHB15 methylation was observed in matched adjacent tissue (P = 0.001) and gastritis tissue (P < 0.001). Interestingly, Kaplain-Meier analysis found that patients with higher PCDHB15 methylation had longer survival as compared to patients with lower methylation (p = 0.03).

Conclusions

Our study indicate that methylated PCDHB15 promoter may be associated with development of gastric cancer. Patients with higher PCDHB15 methylation are prone to have better prognosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This study was supported by a grant from Taichung Veterans General Hospital (RVHYCY-107008).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.